Phaseline

Companies › Shattuck Labs

Shattuck Labs: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Immunology, Other; next expected readout Jul 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SL-325
DR3 blocking antibody
TNFRSF25Phase 2Crohn's Disease; Healthy VolunteersJul 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07158437SL-325Phase 1Healthy VolunteersOtherJul 2026
NCT07753850SL-325Phase 2Crohn's DiseaseImmunologyJul 2028

From the company's SEC filings

Cash and short-term investments of $196m on 2026-09-30; operating cash outflow about $55m a year; runway about 43 months at that burn, to Apr 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

TNFRSF25 (1)

Companies with the same targets

–

Companies built like this

Oruka Therapeutics Clarent Biopharma Abivax QED Therapeutics, a BridgeBio company Kymera Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.